Profile data is unavailable for this security.
About the company
Hangzhou Alltest Biotech Co Ltd is a China-based company mainly engaged in the development and production of in vitro diagnostic reagents. The Company’s main products are rapid diagnostic reagents, including drug and drug abuse testing, infectious disease testing, women’s health testing, tumor testing, and heart marker testing. The Company's products are widely used in clinical testing, on-site testing and personal health management, especially in some new drug testing, new coronavirus testing, tropical infectious disease testing, respiratory all-in-one inspection, pediatric diarrhea all-in-one inspection and all-in-one joint inspection of fecal occult blood and other fields. The Company's main business is mainly distributed in overseas regions.
- Revenue in CNY (TTM)812.78m
- Net income in CNY276.54m
- Incorporated2009
- Employees1.09k
- LocationHangzhou Alltest Biotech Co LtdFactory Building No. 3, 4, & 5, No. 550Yinhai Street, Baiyang NeighborhoodHangzhou Economic and Technological DeveHANGZHOU 310018ChinaCHN
- Phone+86 57 156207860
- Fax+86 57 156267856
- Websitehttps://www.alltests.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Bioperfectus Technologies Co Ltd | 394.84m | -170.68m | 4.59bn | 684.00 | -- | 1.40 | -- | 11.62 | -2.91 | -2.91 | 6.74 | 58.00 | 0.097 | 0.9747 | 2.52 | 577,244.10 | -4.19 | 25.41 | -4.74 | 31.26 | 65.70 | 63.37 | -43.23 | 32.86 | 4.96 | -- | 0.0903 | 30.54 | -92.72 | 11.81 | -120.45 | -- | 2.43 | -- |
| TINAVI Medical Technologies Co Ltd | 168.49m | -160.48m | 4.60bn | 339.00 | -- | 3.90 | -- | 27.29 | -0.3585 | -0.3585 | 0.3756 | 2.62 | 0.1075 | 1.48 | 4.73 | 475,961.90 | -10.24 | -7.86 | -11.04 | -9.07 | 68.66 | 73.58 | -95.24 | -50.09 | 2.21 | -- | 0.1532 | -- | 34.48 | 10.63 | -41.42 | -- | 51.87 | -- |
| Assure Tech Hangzhou Co Ltd | 590.49m | 90.50m | 4.80bn | 791.00 | 53.04 | 0.9316 | -- | 8.13 | 0.712 | 0.712 | 4.65 | 40.53 | 0.1011 | 1.90 | 2.85 | 746,504.60 | 1.55 | 31.83 | 1.71 | 38.97 | 36.87 | 65.82 | 15.30 | 47.86 | 8.66 | -- | 0.0125 | 16.05 | -91.84 | 25.18 | -95.35 | 33.51 | 78.77 | -- |
| Beijing Chunlizhengda Mdicl Instr Co Ltd | 924.65m | 158.35m | 4.82bn | 1.23k | 34.75 | 1.94 | -- | 5.21 | 0.4078 | 0.4078 | 2.41 | 7.29 | 0.2698 | 0.5381 | 2.15 | 751,138.90 | 4.62 | 12.53 | 5.49 | 15.43 | 71.08 | 72.76 | 17.12 | 26.89 | 3.80 | -- | 0.0003 | 21.63 | 0.5759 | 19.40 | -9.72 | 21.33 | -8.60 | -- |
| Zhejiang Gongdong Medical Techno Co Ltd | 1.10bn | 162.27m | 4.90bn | 1.67k | 30.17 | 2.94 | -- | 4.46 | 1.03 | 1.03 | 6.95 | 10.57 | 0.5684 | 6.55 | 4.33 | 656,174.20 | 8.40 | 16.35 | 9.71 | 19.26 | 32.48 | 41.19 | 14.77 | 21.62 | 3.00 | -- | 0.0521 | 38.99 | -33.61 | 15.11 | -66.53 | 5.14 | 27.71 | -- |
| Hangzhou Ags Medtech Co Ltd | 590.12m | 271.52m | 4.95bn | 592.00 | 18.21 | 2.15 | -- | 8.39 | 3.36 | 3.36 | 7.30 | 28.53 | 0.2545 | 3.27 | 13.92 | 996,828.30 | 11.71 | -- | 12.26 | -- | 71.52 | -- | 46.01 | -- | 19.56 | -- | 0.003 | -- | 37.09 | -- | 49.87 | -- | -- | -- |
| Xiangyu Medical Co Ltd | 709.56m | 121.39m | 5.18bn | 1.82k | 42.02 | 2.56 | -- | 7.30 | 0.77 | 0.77 | 4.52 | 12.66 | 0.2596 | 1.01 | 14.80 | 390,085.10 | 4.44 | 11.18 | 5.62 | 13.12 | 66.03 | 66.78 | 17.12 | 32.69 | 1.43 | -- | 0.1417 | 27.33 | 52.46 | 15.72 | 81.03 | 23.11 | 132.76 | -- |
| Hangzhou Alltest Biotech Co Ltd | 812.78m | 276.54m | 5.25bn | 1.09k | 18.94 | 1.32 | -- | 6.46 | 3.50 | 3.50 | 10.26 | 50.02 | 0.198 | 2.21 | 6.97 | 743,626.50 | 6.74 | 23.35 | 7.22 | 26.83 | 53.69 | 58.34 | 34.03 | 39.07 | 10.46 | -- | 0.0022 | 29.79 | -77.73 | 32.59 | -84.75 | 26.19 | 72.77 | -- |
| Shanghai Sanyou Medical Co Ltd | 434.20m | 37.87m | 5.26bn | 466.00 | 147.82 | 2.75 | -- | 12.11 | 0.1432 | 0.1432 | 1.71 | 7.69 | 0.1951 | 0.6191 | 5.15 | 931,756.40 | 2.09 | 9.42 | 2.41 | 10.85 | 70.72 | 87.15 | 10.73 | 29.78 | 3.27 | -- | 0.0135 | 16.21 | -29.08 | 15.67 | -49.91 | 8.99 | -15.60 | -- |
| Innovita Biological Technology Co Ltd | 720.40m | 332.01m | 5.82bn | 404.00 | 17.46 | 2.85 | -- | 8.07 | 2.44 | 2.44 | 5.30 | 14.98 | 0.3584 | 3.18 | 9.16 | 1,783,177.00 | 16.52 | -- | 17.42 | -- | 80.70 | -- | 46.09 | -- | 16.01 | -- | 0.001 | -- | 7.03 | -- | 15.44 | -- | -- | -- |
Data as of Nov 15 2024. Currency figures normalised to Hangzhou Alltest Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
19.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 3.59m | 9.58% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2024 | 2.16m | 5.76% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 326.37k | 0.87% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 287.77k | 0.77% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024 | 221.66k | 0.59% |
| Invesco Hong Kong Ltd.as of 30 Sep 2024 | 215.40k | 0.58% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2024 | 213.60k | 0.57% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024 | 83.93k | 0.22% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 73.18k | 0.20% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 52.60k | 0.14% |
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
